Approval was based on results from the Phase II TROPION-Lung05 trial, which showed that Datroway demonstrated a strong ...

AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC ...

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or ...

The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said Datroway has secured US Food & Drug Administration approval for use in adult patients with previously treated advanced ...

AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition. Find out why AZN stock is a hold.

Expanding eligibility criteria for lung cancer screening to include 20-year smoking history without requiring a certain ...

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

AstraZeneca welcomed NICE’s decision, which expands access beyond previous eligibility criteria set in 2022. It aligns with a recent acceptance by the Scottish Medicines Consortium (SMC) for the same ...